Consistently, PGC-1α has been suggested as a promising therapeutic target for HD and PD, either by boosting PGC-1α expression by viral delivery, or by modulating the upstream activators of PGC-1α activity, such as SIRT1 and AMPK (126). Here, PPARGC1A is linked to Parkinson disease.